The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
 
Damien Pouessel
Honoraria - Amgen; Astellas Pharma; Boehringer Ingelheim; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Lilly; MSD Oncology; Novartis; Roche; Sanofi
Research Funding - Amgen (Inst); MSD Oncology (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis; Sanofi
 
Augustin Mervoyer
No Relationships to Disclose
 
Delphine Larrieu-Ciron
No Relationships to Disclose
 
Bastien Cabarrou
No Relationships to Disclose
 
Justine Attal
No Relationships to Disclose
 
Marie Robert
No Relationships to Disclose
 
Jean-Sebastien Frenel
Consulting or Advisory Role - AstraZeneca; Lilly; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Pascale Olivier
No Relationships to Disclose
 
Muriel Poublanc
No Relationships to Disclose
 
Muriel Mounier
No Relationships to Disclose
 
Elizabeth Moyal
Honoraria - Accuray; Brainlab
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Accuray; AstraZeneca